Published in Clin Ther on April 01, 2006
Multiple sclerosis review. P T (2012) 1.34
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood (2008) 1.11
Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci (2009) 0.94
T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunotherapy (2010) 0.86
Mitoxantrone therapy for acute posterior multifocal placoid pigment epitheliopathy with cerebral vasculitis. Case Rep Med (2009) 0.82
A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation. Oncotarget (2015) 0.82
Inhibiting AKT phosphorylation employing non-cytotoxic anthraquinones ameliorates TH2 mediated allergic airways disease and rhinovirus exacerbation. PLoS One (2013) 0.82
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav (2015) 0.80
Asymmetric enzymatic glycosylation of mitoxantrone. Org Lett (2011) 0.80
Identification association of drug-disease by using functional gene module for breast cancer. BMC Med Genomics (2015) 0.80
Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics. EPMA J (2010) 0.79
3,3'-diindolylmethane ameliorates experimental autoimmune encephalomyelitis by promoting cell cycle arrest and apoptosis in activated T cells through microRNA signaling pathways. J Pharmacol Exp Ther (2014) 0.79
Predictive value of imaging markers at multiple sclerosis disease onset based on gadolinium- and USPIO-enhanced MRI and machine learning. PLoS One (2014) 0.79
New and emerging immune-targeted drugs for the treatment of multiple sclerosis. Br J Clin Pharmacol (2014) 0.77
Rapid and extensive collapse from electrically responsive macroporous hydrogels. Adv Healthc Mater (2013) 0.77
Redox Events As Modulators of Pathology and Therapy of Neuroinflammatory Diseases. Front Cell Dev Biol (2016) 0.75
Intractable and highly active relapsing multiple sclerosis - role of alemtuzumab. Neuropsychiatr Dis Treat (2015) 0.75